Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to $39.6 million.

  • Editas Medicine's Cash from Investing Activities fell 52.88% to $39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.6 million, marking a year-over-year decrease of 12.61%. This contributed to the annual value of $162.1 million for FY2024, which is 4445.91% up from last year.
  • Per Editas Medicine's latest filing, its Cash from Investing Activities stood at $39.6 million for Q3 2025, which was down 7.21% from $42.6 million recorded in Q2 2025.
  • Editas Medicine's Cash from Investing Activities' 5-year high stood at $89.2 million during Q3 2022, with a 5-year trough of -$102.8 million in Q3 2023.
  • Moreover, its 3-year median value for Cash from Investing Activities was $39.6 million (2025), whereas its average is $27.0 million.
  • As far as peak fluctuations go, Editas Medicine's Cash from Investing Activities surged by 1,637.70% in 2022, and later plummeted by 215.23% in 2023.
  • Editas Medicine's Cash from Investing Activities (Quarterly) stood at -$22.8 million in 2021, then declined by 20.53% to -$27.5 million in 2022, then skyrocketed by 328.28% to $62.8 million in 2023, then plummeted by 50.74% to $31.0 million in 2024, then plummeted by 52.88% to $39.6 million in 2025.
  • Its last three reported values are $39.6 million in Q3 2025, $42.6 million for Q2 2025, and $56.4 million during Q1 2025.